Metformin attenuates cartilage degeneration in an experimental osteoarthritis model by regulating AMPK/mTOR | Zendy

Xiaofeng Feng | Zendy; Jianying Pan | Zendy; Junyan Li | Zendy; Chun Zeng | Zendy; Weizhong Qi | Zendy; Yan Shao | Zendy; Xin Liu | Zendy; Liangliang Liu | Zendy; Guozhi Xiao | Zendy; Haiyan Zhang | Zendy; Xiaochun Bai | Zendy; Daozhang Cai | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Metformin attenuates cartilage degeneration in an experimental osteoarthritis model by regulating AMPK/mTOR

Author(s) -

Xiaofeng Feng,

Jianying Pan,

Junyan Li,

Chun Zeng,

Weizhong Qi,

Yan Shao,

Xin Liu,

Liangliang Liu,

Guozhi Xiao,

Haiyan Zhang,

Xiaochun Bai,

Daozhang Cai

Publication year - 2020

Publication title -

aging

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.473

H-Index - 90

ISSN - 1945-4589

DOI - 10.18632/aging.102635

Subject(s) - ampk , metformin , pi3k/akt/mtor pathway , osteoarthritis , degeneration (medical) , cartilage , medicine , endocrinology , microbiology and biotechnology , protein kinase a , anatomy , biology , diabetes mellitus , pathology , signal transduction , phosphorylation , alternative medicine

It is generally thought that the occurrence and progression of osteoarthritis (OA) results from multiple causes, including degradation and destruction of the cartilage matrix and aging of chondrocytes. Metformin is a first-line drug for the treatment of diabetes, and has great potential for the treatment of other disorders. However, the role of metformin in OA is unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research